United States · 
What does Brookside Capital invest in?
Brookside Capital invests most often at Series C and Series D (53% of the rounds on record), in sectors such as Identity Management, Social Media and Biotechnology.
Brookside Capital highlights
- 01
40 rounds on record
- 02
Mostly Series C and Series D: 53% of its rounds
- 03
10 exits from the portfolio
What they do
- Type
- Hedge fund (from a list, unverified)
- Cheque size
- Not stated
- Sectors
- Identity ManagementSocial MediaBiotechnology
- Based in
- United States
- Cold pitches
- Not stated
A website was listed for this organisation, but we could not confirm it belongs to the firm that wrote these cheques. Either the site never mentions them, or it turned out to be a different company sharing the name. We show neither it nor anything read from it. Tell us the right one.
The record
Every round we can evidence, newest first40 appearances
- 2015
8 rounds
- Sept
- Jul
- Jul
- May
- May
- May
- Apr
- Jan
- 2014
3 rounds
- May
- May
- Feb
- 2013
4 rounds
- Dec
- Jul
- Apr
- Mar
- 2012
1 round
- Feb
- 2011
2 rounds
- Dec
- Jul
- 2010
1 round
- Apr
- 2009
3 rounds
- Dec
- Jun
- Mar
- 2008
4 rounds
- Jun
- May
- Apr
- Mar
- 2007
8 rounds
- Dec
- Nov
- Nov
- May
- Mar
- Feb
- Jan
- Jan
- 2006
2 rounds
- Nov
- Jun
- 2005
3 rounds
- May
- Feb
- Feb
- 2004
1 round
- Mar
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration24 named
AMAdam Max KoppelExecutive OfficeriFiling they signed
AMAnad MoreExecutive OfficeriFiling they signed
ACAnand Christopher MorePARTNER OF THE INVESTMENT ADVISERiFiling they signed
AWAndrew W. ViensMANAGING DIRECTOR OF THE INVESTMENT ADVISORiFiling they signed
CLCorey L. SclarManaging Member of General PartneriFiling they signed
DDDavid D. ButtolphManaging Member of General PartneriFiling they signed
DMDavis Michael ClaysonExecutive OfficeriFiling they signed
DGDennis G. GoldsteinExecutive OfficeriFiling they signed
DCDevon C. BurgerMember of the General PartneriFiling they signed
DJDewey John AwadMANAGING DIRECTOR OF THE INVESTMENT ADVISORiFiling they signed
DJDomenic Jay FerranteExecutive OfficeriFiling they signed
DJDouglas J. RudischExecutive OfficeriFiling they signed
EMEd Michael BrakemanExecutive OfficeriFiling they signed
EFEmily F. MccombExecutive OfficeriFiling they signed
FMFerat Michael OngorenMANAGING DIRECTOR OF THE INVESTMENT ADVISORiFiling they signed
FMFernando Michael VigilExecutive OfficeriFiling they signed
GCGregory C. FoyMember of the General PartneriFiling they signed
GWGregory William MooreExecutive OfficeriFiling they signed
JMJohn Michael ToussaintPARTNER OF THE INVESTMENT ADVISERiFiling they signed
JLJohn L. Irwin IIIManaging Member of General PartneriFiling they signed
JNJohn N. IrwinMember of the General PartneriFiling they signed
JMJoshua Michael RossMANAGING DIRECTOR AND CHIEF INVESTMENT OFFICER OF THE INVESTMENT ADVISORiFiling they signed
MCMark Christopher MooreExecutive OfficeriFiling they signed
MMMark McpherronExecutive OfficeriFiling they signed
We also hold 74 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
Exits from the portfolio
Companies it backed that were later bought or listed10 in all
PTC TherapeuticsListed$125MJun 2013
Portola PharmaceuticalsListed$100MMay 2013
MAP PharmaceuticalsBought by Allergan$958MJan 2013
BrightcoveListedUndisclosedFeb 2012
ThumbplayBought by iHeartMediaUndisclosedMar 2011
YoukuListedUndisclosedDec 2010
TengionListedUndisclosedApr 2010
Virtual Iron SoftwareBought by Oracle CorporationUndisclosedMay 2009
Eyetel ImagingBought by NeuroMetrix$10MDec 2007
MetaSolvBought by Oracle CorporationUndisclosedOct 2006
An exit counts when it came after the firm's first round in the company. From historical deal records.